Cingulate begins Phase 3 tests of novel treatment for ADHD


Cingulate's technology will let patients receive treatment ADHD treatment without second doses, boosters to get through the day.

Previous UNC economist: Mild recession coming in 2023 but Triad and N.C. seen as resilient
Next Novan seeks FDA approval for lead product